Answers are grounded in this paper and cite their sources.
Diffuse gliomas with H3F3A point mutations affecting histone H3.3 glycine position 34 are a distinct glioma subtype mostly occurring in the cerebral hemispheres of paediatric and young adult patients. These tumours have a high rate of MGMT promoter hypermethylation, a predictive biomarker for response to the DNA alkylating agent temozolomide (TMZ). Post-treatment TMZ-associated hypermutation is a mechanism for TMZ resistance in recurrent isocitrate dehydrogenase (IDH) wildtype glioblastoma and may be seen in association with tumour progression in lower-grade IDH-mutant diffuse astrocytic gliomas.
No takes yet. Share an insight, caveat, or question.
Wood et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: